Accordingly, NSCLC tumors harboring EGFR-activating mutations may be susceptible to treatment with gefitinib, whereas gefitinib exhibits limited efficacy against NSCLC with wild-type EGFR. Here, EGFR is linked to non-small cell lung carcinoma.